Physician profile
Pat Olivas
NPI 1346723731
$650.02
in general payments reported to CMS, 2019-2025
18 companies · $21.76 in 2025
The $21.76 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $418 · 2022: $171 · 2023: $39.53 · 2025: $21.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $112.94 | 2021 | |
| Amgen INC. | $104.08 | 2021-2022 | |
| Janssen Biotech, INC. | $56.23 | 2021-2022 | |
| Daiichi Sankyo INC. | $53.96 | 2021-2022 | |
| Eisai INC. | $44.20 | 2022-2025 | |
| Seagen INC. | $38.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $29.49 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.88 | 2021 | |
| Karyopharm Therapeutics INC. | $24.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $23.28 | 2021 | |
| Medtronic, INC. | $22.74 | 2023 | Interstim |
| Heron Therapeutics, INC. | $21.58 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $16.79 | 2023 | Imbruvica |
| Blueprint Medicines Corporation | $16.39 | 2022 | |
| Amag Pharmaceuticals, INC. | $15.69 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $15.00 | 2021 | |
| Merck Sharp & Dohme LLC | $14.59 | 2021 | |
| Lilly USA, LLC | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pat Olivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.